Pharming reacquires Ruconest-licensed territories from Sobi

30 December 2019

Netherlands-based Pharming Group (Euronext: PHARM) today announced it has entered into a definitive agreement with Swedish Orphan Biovitrum (STO: SOBI; “Sobi”) to reacquire the commercial rights to Pharming’s Ruconest (C1 esterase inhibitor [recombinant]) in all remaining territories, which includes all remaining European Union markets.

Under the agreement, the license is being terminated with effect from January 1, 2020 in all 36 countries with a smooth handover planned in the countries where Sobi has sales activities. Pharming will pay Sobi 7.5 million euros ($8.4 million) in two tranches, the larger part upfront with a final payment once all transition activities are complete or underway. There are no further future payments under this agreement.

Ruconest sales expected to increase

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK